Budur Kumar
Known title: CHIEF MEDICAL OFFICERCIK: 0002009762
Associated companies
Transaction History
| HRMY | ▲ Buy | Option Exercise | 10,406 | $319K | 9/18/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 25,446 | $770K | 9/18/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 35,852 | $1.5M | 9/18/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 400 | $12K | 9/17/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 400 | $12K | 9/17/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 800 | $34K | 9/17/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 900 | $28K | 9/16/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 900 | $27K | 9/16/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 1,800 | $77K | 9/16/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 4,500 | $190K | 9/8/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 1,000 | $43K | 9/8/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 12,200 | $374K | 9/8/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 10,754 | $326K | 9/8/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 22,954 | $989K | 9/8/2026 | View on chart |
| HRMY | ▼ Sell | Open Market | 5,500 | $231K | 9/4/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 18,750 | $0 | 5/1/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 8,882 | $283K | 5/1/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 2,662 | $0 | 1/25/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 1,372 | $51K | 1/25/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 2,188 | $0 | 1/24/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 1,153 | $42K | 1/24/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 18,750 | $0 | 5/1/2025 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 8,869 | $265K | 5/1/2025 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 2,187 | $0 | 1/24/2025 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 1,151 | $44K | 1/24/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.